Prof Klaus Dugi, Medical Director, Boehringer Ingelheim UK and Ireland
Klaus first joined Boehringer Ingelheim in 2003 to translate the pre-clinical diabetes pipeline into clinical research. Klaus is an internist and endocrinologist by training and prior to joining Boehringer Ingelheim, he was heading the Metabolic Outpatient Clinic at Heidelberg University Hospital where he continues to teach Internal Medicine. Klaus also spent four years in the US to conduct research at the National Institutes of Health in Bethesda, Maryland.
During his more than 12 years at BI, Klaus has served roles in Clinical Operations and Clinical Development and held the positions Head of Global Medical Affairs and Therapeutic Area Head Medicine Metabolic Diseases. Klaus joins us from his current role in Corporate as Chief Medical Officer. He will bring a deep knowledge of our recently launched and currently developed medicines as well as a thorough understanding of BI from a global and Corporate medical perspective.
Duncan Cantor, Communications Director, Boehringer Ingelheim UK and Ireland
Duncan Cantor is the UK and Ireland communications director for the family owned pharmaceutical company Boehringer Ingelheim. Since joining Boehringer
Ingelheim in 2008 he has held government affairs and communication roles in the UK and globally.
Working across sectors and roles has given Duncan a distinct perspective on patient engagement in healthcare, and thorough his career in Boehringer Ingelheim, Duncan has worked on projects and initiatives that have focused on putting the patient front and centre in the company’s thinking.
Prior to his current role, he worked in sectors including banking and private healthcare.